<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30036863</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>07</Month>            <Day>31</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1423-0232</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>94 Suppl 1</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Oncology</Title>                <ISOAbbreviation>Oncology</ISOAbbreviation>            </Journal>            <ArticleTitle>Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.</ArticleTitle>            <Pagination>                <MedlinePgn>3-5</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000489061</ELocationID>            <Abstract>                <AbstractText>Despite the wide pharmacological armamentarium available for the treatment of metastatic breast cancer (MBC), long-lasting control of disease is challenging, especially in heavily pretreated patients. In this case report, we documented a long-lasting complete response (CR) with eribulin in a relatively young woman with MBC and bone metastasis, who did not benefit from prior chemotherapy regimens. Besides CR, the patient was able to maintain an excellent performance status and was free from the severe pain experienced before the initiation of eribulin. Noteworthy, eribulin treatment was very well tolerated, with only a mild alopecia being reported; response was maintained also after a temporary dose interruption and a therapeutic holiday due to non-treatment-related increase in liver enzymes and steatosis.</AbstractText>                <CopyrightInformation>Â© 2018 S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Medici</LastName>                    <ForeName>Marta</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Fossile</LastName>                    <ForeName>Emanuela</ForeName>                    <Initials>E</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Oncology</MedlineTA>            <NlmUniqueID>0135054</NlmUniqueID>            <ISSNLinking>0030-2414</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>LR24G6354G</RegistryNumber>                <NameOfSubstance UI="C490954">eribulin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2015;11(15 Suppl):3-8</RefSource>                <PMID Version="1">26235258</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2008 Jul;7(7):2003-11</RefSource>                <PMID Version="1">18645010</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Mar 12;377(9769):914-23</RefSource>                <PMID Version="1">21376385</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2011 Jan 15;71(2):496-505</RefSource>                <PMID Version="1">21127197</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2017 Apr;13(11s):35-43</RefSource>                <PMID Version="1">28481188</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Future Oncol. 2017 Apr;13(11s):25-33</RefSource>                <PMID Version="1">28481183</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer (Auckl). 2016 Jun 28;10:77-84</RefSource>                <PMID Version="1">27398025</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Feb 20;33(6):594-601</RefSource>                <PMID Version="1">25605862</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Bone metastasis</Keyword>            <Keyword MajorTopicYN="N">Eribulin </Keyword>            <Keyword MajorTopicYN="N">Long-lasting complete response </Keyword>            <Keyword MajorTopicYN="N">Metastatic breast cancer </Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>1</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30036863</ArticleId>            <ArticleId IdType="pii">000489061</ArticleId>            <ArticleId IdType="doi">10.1159/000489061</ArticleId>            <ArticleId IdType="pmc">PMC6193745</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>